Good job! 👍-To The Moon - Tiger Brokers Online Investing Community - To The Moon

3
Comment
Favorite

firefirefire
11-03

Good job! 👍

Terns Pharmaceuticals Stock Soars on Promising Data for CML Therapy

$Terns Pharmaceuticals(TERN)$ stock surged 81.6% in morning trading on Monday after the clinical-stage oncology company reported promising data from its ongoing CARDINAL trial of TERN-701, a novel...

Terns Pharmaceuticals Stock Soars on Promising Data for CML Therapy

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

3

Report

Comment

Top
Latest

empty

No comments yet

Most Discussed

{"i18n":{"language":"en_US"},"data":{"magic":2,"id":496281679135240,"tweetId":"496281679135240","gmtCreate":1762184942238,"gmtModify":1762184945955,"author":{"id":3570742778586711,"idStr":"3570742778586711","authorId":3570742778586711,"authorIdStr":"3570742778586711","name":"firefirefire","avatar":"https://community-static.tradeup.com/news/e33159cc1bfc6784fa479fe87a11fd33","vip":1,"userType":1,"introduction":"","boolIsFan":false,"boolIsHead":false,"crmLevel":11,"crmLevelSwitch":1,"currentWearingBadge":{"badgeId":"a83d7582f45846ffbccbce770ce65d84-1","templateUuid":"a83d7582f45846ffbccbce770ce65d84","name":"Real Trader","description":"Completed a transaction","bigImgUrl":"https://static.tigerbbs.com/2e08a1cc2087a1de93402c2c290fa65b","smallImgUrl":"https://static.tigerbbs.com/4504a6397ce1137932d56e5f4ce27166","grayImgUrl":"https://static.tigerbbs.com/4b22c79415b4cd6e3d8ebc4a0fa32604","redirectLinkEnabled":0,"hasAllocated":1,"isWearing":1,"stampPosition":0,"hasStamp":0,"allocationCount":1,"allocatedDate":"2021.12.21","individualDisplayEnabled":0},"individualDisplayBadges":[],"fanSize":224,"starInvestorFlag":false},"themes":[],"images":[],"coverImages":[],"title":"","html":"<html><head></head><body><p>Good job! 👍&nbsp;</p></body></html>","htmlText":"<html><head></head><body><p>Good job! 👍&nbsp;</p></body></html>","text":"Good job! 👍","highlighted":1,"essential":1,"paper":1,"likeSize":3,"commentSize":0,"repostSize":0,"favoriteSize":0,"link":"https://ttm.financial/post/496281679135240","repostId":1116417566,"repostType":4,"repost":{"id":"1116417566","kind":"news","weMediaInfo":{"introduction":"Providing stock market headlines, business news, financials and earnings ","home_visible":1,"media_name":"Tiger Newspress","id":"1079075236","head_image":"https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba"},"pubTimestamp":1762184400,"share":"https://ttm.financial/m/news/1116417566?lang=en_US&edition=fundamental","pubTime":"2025-11-03 23:40","market":"us","language":"en","title":"Terns Pharmaceuticals Stock Soars on Promising Data for CML Therapy","url":"https://stock-news.laohu8.com/highlight/detail?id=1116417566","media":"Tiger Newspress","summary":"$Terns Pharmaceuticals(TERN)$ stock surged 81.6% in morning trading on Monday after the clinical-stage oncology company reported promising data from its ongoing CARDINAL trial of TERN-701, a novel...","content":"<html><head></head><body><p><a href=\"https://laohu8.com/S/TERN\">Terns Pharmaceuticals</a> stock surged 81.6% in morning trading on Monday after the clinical-stage oncology company reported promising data from its ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for chronic myeloid leukemia (CML).</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/0475f80f159f6ccffb354578fe3cdfb0\" tg-width=\"539\" tg-height=\"133\"/></p><p style=\"text-align: start;\">The data, selected for oral presentation at the upcoming 67th American Society of Hematology Annual Meeting in December, showed a 75% overall major molecular response (MMR) rate by 24 weeks among 32 efficacy-evaluable patients with previously treated CML.</p><p style=\"text-align: start;\">The company highlighted strong efficacy in difficult-to-treat patient subgroups, with 69% MMR rates in patients who lacked efficacy to their last tyrosine kinase inhibitor (TKI) and 60% in those with prior asciminib treatment. No patients had lost MMR at the time of the data cutoff.</p><p style=\"text-align: start;\">&#34;The 24 weeks MMR achievement rate with TERN-701 is unprecedented, trending at least two times higher than the rates reported in other Phase 1 studies of CML therapies that are approved or in development,&#34; said Amy Burroughs, chief executive officer of Terns.</p><p style=\"text-align: start;\">The trial enrolled heavily pretreated patients with a median of three prior TKIs, with 35% having received four or more prior treatments. Despite this challenging population, the drug demonstrated an encouraging safety profile with mostly low-grade adverse events.</p><p style=\"text-align: start;\">The most common side effects were diarrhea (22%), headache (18%), and nausea (16%), all Grade 1 or 2. Higher-grade adverse events occurred in less than 10% of patients, primarily neutropenia (7%) and thrombocytopenia (4%).</p><p style=\"text-align: start;\">The company plans to present expanded and updated data from the CARDINAL trial at the ASH Annual Meeting in December, followed by an investor conference call.</p></body></html>","collect":0,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Terns Pharmaceuticals Stock Soars on Promising Data for CML Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nTerns Pharmaceuticals Stock Soars on Promising Data for CML Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1079075236\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/8274c5b9d4c2852bfb1c4d6ce16c68ba);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Tiger Newspress </p>\n<p class=\"h-time\">2025-11-03 23:40</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><head></head><body><p><a href=\"https://laohu8.com/S/TERN\">Terns Pharmaceuticals</a> stock surged 81.6% in morning trading on Monday after the clinical-stage oncology company reported promising data from its ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for chronic myeloid leukemia (CML).</p><p class=\"t-img-caption\"><img src=\"https://community-static.tradeup.com/news/0475f80f159f6ccffb354578fe3cdfb0\" tg-width=\"539\" tg-height=\"133\"/></p><p style=\"text-align: start;\">The data, selected for oral presentation at the upcoming 67th American Society of Hematology Annual Meeting in December, showed a 75% overall major molecular response (MMR) rate by 24 weeks among 32 efficacy-evaluable patients with previously treated CML.</p><p style=\"text-align: start;\">The company highlighted strong efficacy in difficult-to-treat patient subgroups, with 69% MMR rates in patients who lacked efficacy to their last tyrosine kinase inhibitor (TKI) and 60% in those with prior asciminib treatment. No patients had lost MMR at the time of the data cutoff.</p><p style=\"text-align: start;\">&#34;The 24 weeks MMR achievement rate with TERN-701 is unprecedented, trending at least two times higher than the rates reported in other Phase 1 studies of CML therapies that are approved or in development,&#34; said Amy Burroughs, chief executive officer of Terns.</p><p style=\"text-align: start;\">The trial enrolled heavily pretreated patients with a median of three prior TKIs, with 35% having received four or more prior treatments. Despite this challenging population, the drug demonstrated an encouraging safety profile with mostly low-grade adverse events.</p><p style=\"text-align: start;\">The most common side effects were diarrhea (22%), headache (18%), and nausea (16%), all Grade 1 or 2. Higher-grade adverse events occurred in less than 10% of patients, primarily neutropenia (7%) and thrombocytopenia (4%).</p><p style=\"text-align: start;\">The company plans to present expanded and updated data from the CARDINAL trial at the ASH Annual Meeting in December, followed by an investor conference call.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","type":0,"thumbnail":"","relate_stocks":{"TERN":"Terns Pharmaceuticals, Inc."},"source_url":"","is_english":true,"share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","article_id":"1116417566","content_text":"Terns Pharmaceuticals stock surged 81.6% in morning trading on Monday after the clinical-stage oncology company reported promising data from its ongoing CARDINAL trial of TERN-701, a novel investigational allosteric BCR::ABL1 inhibitor for chronic myeloid leukemia (CML).The data, selected for oral presentation at the upcoming 67th American Society of Hematology Annual Meeting in December, showed a 75% overall major molecular response (MMR) rate by 24 weeks among 32 efficacy-evaluable patients with previously treated CML.The company highlighted strong efficacy in difficult-to-treat patient subgroups, with 69% MMR rates in patients who lacked efficacy to their last tyrosine kinase inhibitor (TKI) and 60% in those with prior asciminib treatment. No patients had lost MMR at the time of the data cutoff.\"The 24 weeks MMR achievement rate with TERN-701 is unprecedented, trending at least two times higher than the rates reported in other Phase 1 studies of CML therapies that are approved or in development,\" said Amy Burroughs, chief executive officer of Terns.The trial enrolled heavily pretreated patients with a median of three prior TKIs, with 35% having received four or more prior treatments. Despite this challenging population, the drug demonstrated an encouraging safety profile with mostly low-grade adverse events.The most common side effects were diarrhea (22%), headache (18%), and nausea (16%), all Grade 1 or 2. Higher-grade adverse events occurred in less than 10% of patients, primarily neutropenia (7%) and thrombocytopenia (4%).The company plans to present expanded and updated data from the CARDINAL trial at the ASH Annual Meeting in December, followed by an investor conference call.","news_type":1,"symbols_score_info":{"TERN":2}},"isVote":1,"tweetType":1,"viewCount":659,"commentLimit":10,"likeStatus":false,"favoriteStatus":false,"reportStatus":false,"symbols":[],"verified":2,"subType":0,"readableState":1,"langContent":"EN","currentLanguage":"EN","warmUpFlag":false,"orderFlag":false,"shareable":true,"causeOfNotShareable":"","featuresForAnalytics":[],"commentAndTweetFlag":false,"andRepostAutoSelectedFlag":false,"upFlag":false,"length":10,"optionInvolvedFlag":false,"xxTargetLangEnum":"ORIG"},"commentList":[],"hasMoreComment":false,"orderType":2}